Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0484429065743945 -0.013840830449827 -0.0242214532871973 -0.0242214532871973
Stock impact report

Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study

ACHISON INC A (ACHN) 
Last achison inc a earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.achillion.com/investor-relations
Company Research Source: GlobeNewswire
- Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) – - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers– NEW HAVEN, Conn., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ACH-4471 for the treatment of patients with C3 Glomerulopathy (C3G). C3G is a devastating renal disease for which there is no approved therapy. There are estimated to be approximately 4,000 C3G patients in the United States, approximately 4,000 in Europe, and more than 1,000 patients with this devastating disease in Japan. The FDA Orphan Drug Designation program provides incentives for the development of potentially promising drugs to treat, diagnose Show less Read more
Impact Snapshot
Event Time:
ACHN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ACHN alerts
Opt-in for
ACHN alerts

from News Quantified
Opt-in for
ACHN alerts

from News Quantified